Plexxikon and Merck to Collaborate on Combination Study Evaluating Investigational Immuno-oncology Regimen
Dateline City:
BERKELEY, Calif., and KENILWORTH, N.J.
Study will Evaluate Merck’s Anti-PD-1 Therapy, KEYTRUDA® (pembrolizumab),
in Combination with Plexxikon’s PLX3397
BERKELEY, Calif., and KENILWORTH, N.J. – Plexxikon Inc., a member of Daiichi Sankyo Group, and Merck (NYSE:MRK), known as MSD outside the US and Canada, through a subsidiary, today announced a collaborative clinical trial that will evaluate the combination of PLX3397, Plexxikon’s investigational CSF-1R inhibitor, and KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, which provides the potential for a double blockade of cancer-induced immune suppression.
Language:
English
read more
Source: Merck.com - Product News - Category: Drugs & Pharmacology Tags: Oncology Newsroom Prescription Medicine News Research and Development News Corporate News Latest News Source Type: news